This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This program will evaluate the antiviral efficacy of chemically modified siRNA preparations for the treatment of GBV-B infection in the marmoset, a surrogate model of hepatitis C virus (HCV). This project will be conducted in two phases. In phase I, 6 marmosets will be infected with a chimeric GBV-B virus that contains a short HCV sequence in domain III of the IRES structure. Animals will be treated by intravenous administration of antiviral siRNA preparation beginning on day 1 after infection or 4 weeks after GBV-B inoculation. The animals will be monitored to determine the safety of the compound in a non-human primate model and the efficacy of the therapy for inhibition of GBV-B infection.
Showing the most recent 10 out of 444 publications